Ticker Details
Atossa Therapeutics, Inc. Atossa Genetics Inc mainly focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions.
IPO Date:	November 8, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$25.15M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.11 | 5.24%
Avg Daily Range (30 D):	$0.09 | 3.76%
Avg Daily Range (90 D):	$0.13 | 4.06%

Institutional Daily Volume
Avg Daily Volume:	1.76M
Avg Daily Volume (30 D):	.05M
Avg Daily Volume (90 D):	.1M

Trade Size
Avg Trade Size (Sh.):	389
Avg Trade Size (Sh.) (30 D):	162
Avg Trade Size (Sh.) (90 D):	125

Institutional Trades
Total Institutional Trades:	168
Avg Institutional Trade:	$2.14M
Avg Institutional Trade (30 D):	$3.98M
Avg Institutional Trade (90 D):	$3.98M
Avg Institutional Trade Volume:	.04M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$5.33M
Avg Closing Trade (30 D):	$9.36M
Avg Closing Trade (90 D):	$9.36M
Avg Closing Volume:	106.53K

News

May 26, 2026 @ 5:00 PM Duchenne Muscular Dystrophy Clinical Trial Pipelin... Source: Delveinsight

May 8, 2026 @ 12:45 PM Atossa Therapeutics Reports First Quarter 2026 Fin... Source: Atossa Therapeutics Inc

Mar 19, 2026 @ 3:00 PM The Patent Cliff is Coming, Driving Smart Money To... Source: Equity-Insider.Com

Aug 28, 2025 @ 12:30 PM Atossa Therapeutics CEO to Discuss Clinical Progre... Source: Prnewswire

Oct 14, 2024 @ 9:08 PM Atossa Therapeutics to Present at the 2024 Maxim H... Source: N/A

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-5.99	$-.95	$-1.11
Diluted EPS	$-5.99	$-.95	$-1.11
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-37.71M	$-8.49M	$-9.59M
Operating Income / Loss	$-39.25M	$-8.69M	$-9.87M
Cost of Revenue
Net Cash Flow	$M	$9.58M	$-9.58M
PE Ratio

Splits
Feb 02, 2026	1:15
Apr 20, 2018	1:12
Aug 26, 2016	1:15